Business, energy, technology, markets and global industry news from Business News Today

ruxolitinib

PharmaDeviceNews ruxolitinib
Pharma & Biotech

Ipsen closes up to $1.75bn Kartos deal as navtemadlin enters its decisive Phase 3 myelofibrosis test

Ipsen has completed its Kartos Therapeutics acquisition, paying $450 million upfront with up to $1.3 billion in milestones while the 600-patient POIESIS trial tests navtemadlin plus ruxolitinib.

Read More
Representative image: Hematology researchers review blood analysis data as Incyte Corporation’s INCA033989 data highlight potential progress in CALR-mutated myelofibrosis and essential thrombocythemia treatment.
Pharma & Biotech

Why Incyte INCA033989 could reshape essential thrombocythemia and myelofibrosis care

Find out how Incyte INCA033989 data could reshape CALR-mutated myelofibrosis and essential thrombocythemia treatment.

Read More
Representative image: A hematology clinician reviews treatment data in a clinical lab setting as Incyte’s FDA approval of once-daily Jakafi XR highlights the next phase of ruxolitinib therapy for myelofibrosis, polycythemia vera and graft-versus-host disease.
Pharma & Biotech

Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?

Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.

Read More